PI3K/Akt/mTOR inhibitors in breast cancer

Cancer Biology & Medicine
Joycelyn Jx LeeYoon-Sim Yap

Abstract

Activation of the phosphoinositide 3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway is common in breast cancer. There is preclinical data to support inhibition of the pathway, and phase I to III trials involving inhibitors of the pathway have been or are being conducted in solid tumors and breast cancer. Everolimus, an mTOR inhibitor, is currently approved for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer. In this review, we summarise the efficacy and toxicity findings from the randomised clinical trials, with simplified guidelines on the management of potential adverse effects. Education of healthcare professionals and patients is critical for safety and compliance. While there is some clinical evidence of activity of mTOR inhibition in HR-positive and HER2-positive breast cancers, the benefits may be more pronounced in selected subsets rather than in the overall population. Further development of predictive biomarkers will be useful in the selection of patients who will benefit from inhibition of the PI3K/Akt/mTOR (PAM) pathway.

Citations

Mar 23, 2017·Current Neurology and Neuroscience Reports·Nicole ShonkaManmeet S Ahluwalia
Mar 31, 2017·Cancer Chemotherapy and Pharmacology·Jing ChePeng Zhang
Sep 18, 2020·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·H WanL Wang
Jul 7, 2017·Oncology and Therapy·Adouda Adjiri
Feb 6, 2020·International Journal of Molecular Sciences·Alina Jaglanian, Evangelia Tsiani
Sep 20, 2020·ESMO Open·Byung Woog Kang, Ian Chau
Jun 24, 2018·Scientific Reports·Puja KhannaGyeong Hun Baeg
Jul 25, 2021·Cancers·Alakananda Basu, Christoffer Briggs Lambring

❮ Previous
Next ❯

Methods Mentioned

BETA
contraception

Clinical Trials Mentioned

NCT01610284
NCT01633060
NCT02077933
NCT02216786
NCT02088684
NCT01872260

Software Mentioned

BOLERO
HORIZON

Related Concepts

Related Feeds

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Related Papers

Expert Opinion on Investigational Drugs
Mariana Chavez-MacGregor, A M Gonzalez-Angulo
The Breast : Official Journal of the European Society of Mastology
Sharon Wilks
Annals of Oncology : Official Journal of the European Society for Medical Oncology
C Villarreal-GarzaS Verma
© 2022 Meta ULC. All rights reserved